Literature DB >> 18343890

Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure.

Barbara Metzler1, Patrick Gfeller, Grazyna Wieczorek, Jianping Li, Barbara Nuesslein-Hildesheim, Andreas Katopodis, Matthias Mueller, Volker Brinkmann.   

Abstract

The immunomodulator FTY720 inhibits lymph node (LN) and thymic egress, thereby constraining T cell circulation and reducing peripheral T cell numbers. Here, we analyzed in mouse models the as yet scarcely characterized impact of long-term (up to 6 months) FTY720 exposure on T cell homeostasis and possible consequences for alloreactivity. In green fluorescent protein (GFP) hemopoietic chimeras, the turnover of (initially GFP(-)) peripheral T cell pools was markedly delayed under FTY720, while normal homeostatic differences between CD4 and CD8 T cell sub-populations were retained or amplified further. Homeostatic proliferation was enhanced, and within shrinking T cell pools, the proportions of effector memory phenotype CD4 T cells (CD4T(PEM)) increased in spleens and LNs and of central memory phenotype CD8 T cells (CD8T(PCM)) in LNs. By contrast, the fractions of CD8T(PEM) and CD4T(PCM) remained stably small under FTY720. The enrichment for CD4T(PEM) and CD8T(PCM) correlated with larger proportions of IFNgamma-producing T cells upon nonspecific but not allospecific stimulation. Splenic CD4 T cells from FTY720-treated mice proliferated more strongly upon transfer to semi-allogeneic hosts. However, heart allograft survival was not compromised in FTY720 pre-treated recipients. It correlated with reduced intra-graft CD8 T cells, and the longest surviving transplants contained the highest numbers of CD4 T cells. Thus, continuous FTY720 exposure reveals differential homeostatic responses by memory phenotype CD4 and CD8 T cell sub-populations, and it may enhance alloreactive CD4 T cell proliferation and tissue infiltration without accelerating allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343890     DOI: 10.1093/intimm/dxn023

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  13 in total

Review 1.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 2.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 3.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.

Authors:  Volker Brinkmann
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

Review 4.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

5.  Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.

Authors:  Kimberly A Shafer-Weaver; Michael J Anderson; Katherine Stagliano; Anatoli Malyguine; Norman M Greenberg; Arthur A Hurwitz
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

6.  Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis.

Authors:  Andreas Billich; Thomas Baumruker; Christian Beerli; Marc Bigaud; Christian Bruns; Thomas Calzascia; Andrea Isken; Bernd Kinzel; Erika Loetscher; Barbara Metzler; Matthias Mueller; Barbara Nuesslein-Hildesheim; Bernadette Kleylein-Sohn
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

7.  Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.

Authors:  Graham K Sheridan; Kumlesh K Dev
Journal:  Sci Rep       Date:  2014-05-23       Impact factor: 4.379

8.  Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier.

Authors:  Adéla Nacer; Alexandru Movila; Fabien Sohet; Natasha M Girgis; Uma Mahesh Gundra; P'ng Loke; Richard Daneman; Ute Frevert
Journal:  PLoS Pathog       Date:  2014-12-04       Impact factor: 6.823

9.  Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.

Authors:  Kathrin Bail; Quirin Notz; Damiano M Rovituso; Andrea Schampel; Marie Wunsch; Tobias Koeniger; Verena Schropp; Richa Bharti; Claus-Juergen Scholz; Konrad U Foerstner; Christoph Kleinschnitz; Stefanie Kuerten
Journal:  J Neuroinflammation       Date:  2017-07-24       Impact factor: 8.322

10.  Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.

Authors:  Janos Groh; Kristina Berve; Rudolf Martini
Journal:  Mol Ther       Date:  2017-05-13       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.